KLCM Advisors Inc. Has $18.22 Million Holdings in Bristol Myers Squibb Company $BMY

KLCM Advisors Inc. cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.2% during the 1st quarter, HoldingsChannel.com reports. The fund owned 300,430 shares of the biopharmaceutical company’s stock after selling 19,755 shares during the period. Bristol Myers Squibb accounts for approximately 1.5% of KLCM Advisors Inc.’s portfolio, making the stock its 15th biggest position. KLCM Advisors Inc.’s holdings in Bristol Myers Squibb were worth $18,221,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the period. State Street Corp raised its holdings in Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after buying an additional 1,385,206 shares during the period. Geode Capital Management LLC lifted its stake in Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Norges Bank bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $1,947,272,000. Finally, AQR Capital Management LLC boosted its holdings in shares of Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after buying an additional 16,332,924 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Down 0.7%

Shares of BMY stock traded down $0.41 during trading on Friday, reaching $57.53. The company’s stock had a trading volume of 11,202,444 shares, compared to its average volume of 12,071,738. The business has a fifty day moving average price of $56.83 and a 200-day moving average price of $57.62. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The company has a market cap of $117.49 billion, a price-to-earnings ratio of 16.16, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter last year, the firm earned $1.80 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bank of America lowered its price target slightly to $66 from $67 but kept a Buy rating, signaling continued upside potential for Bristol Myers Squibb. Benzinga
• Positive Sentiment: Bristol Myers Squibb’s addition to defensive and value-defensive Russell indices could broaden demand from index-tracking and conservative institutional investors. Yahoo Finance
• Positive Sentiment: The company’s QUILS lung cancer detection program is expanding into new states, reinforcing its reputation in oncology and public-health initiatives. Yahoo Finance

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BMY shares. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Bank of America reduced their target price on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday. HSBC increased their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday, July 6th. Finally, UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $61.25.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.